Robert W. Baird Upgrades Tempus AI (NASDAQ:TEM) to Strong-Buy

Tempus AI (NASDAQ:TEM) was upgraded by analysts at Robert W. Baird to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

TEM has been the topic of a number of other research reports. BTIG Research raised their price objective on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Canaccord Genuity Group decreased their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. JPMorgan Chase & Co. dropped their price objective on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Morgan Stanley raised their target price on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, Piper Sandler dropped their price target on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.64.

Tempus AI Stock Performance

NASDAQ TEM opened at $52.56 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The stock’s 50 day simple moving average is $63.26 and its 200-day simple moving average is $73.60. The company has a market cap of $9.35 billion, a PE ratio of -44.17 and a beta of 5.22. Tempus AI has a 1-year low of $36.22 and a 1-year high of $104.32.

Insider Buying and Selling

In related news, EVP Erik Phelps sold 1,302 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total value of $87,780.84. Following the completion of the transaction, the executive vice president directly owned 89,280 shares in the company, valued at approximately $6,019,257.60. This represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. This trade represents a 15.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 710,438 shares of company stock worth $48,629,758 over the last ninety days. 26.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the business. Renaissance Capital LLC lifted its position in Tempus AI by 26.9% in the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after buying an additional 17,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $1,695,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Tempus AI by 66.8% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 190,828 shares of the company’s stock worth $15,402,000 after purchasing an additional 76,455 shares during the period. Finally, Pier 88 Investment Partners LLC acquired a new stake in Tempus AI in the 2nd quarter valued at approximately $286,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.